BioNTech Q3 revenues up on COVID
Total revenues were estimated to be €6,087.3 million for the three months ended September 30, 2021.
During the three months ended September 30, 2021, BioNTech’s commercial revenues included an estimated amount of €4,341.5 million gross profit share and €17.0 million of sales milestones.
Cash and cash equivalents as of September 30, 2021 were €2,392.7 million.
In addition, trade receivables remained outstanding which is mainly due to the contractual settlement of the gross profit share under the COVID-19 collaboration with Pfizer, which has a temporal offset of more than one calendar quarter.
As Pfizer’s fiscal quarter for subsidiaries outside the United States differs from BioNTech’s financial reporting cycle, it creates an additional time lag between the recognition of revenues and the payment receipt.
Consequently, these trade receivables which are subject to this temporal offset and were outstanding as of September 30, 2021 were received as payments in October 2021, improving BioNTech’s cash position. ■